Drug intelligence / Profile preview

RS33

Development stage: Preclinical
Lead developer: Haixi New Pharma
Modality: Small Molecules

Overview

RS33 is a novel indole derivative identified as a promising glucokinase activator (GKA) for the treatment of type 2 diabetes. Computational studies indicate it has a high binding affinity for glucokinase receptors and exhibits a favorable pharmacokinetic profile, adhering to Lipinski's Rule. Importantly, it has shown no AMES toxicity, skin sensitization, or hepatotoxicity in comparative analyses with standard GKAs like Dorzagliatin. These attributes position RS33 as a potential lead molecule for further optimization in diabetes therapy.

Targets

GCK (Glucokinase)

Beyond the preview

Go deeper on RS33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS33.

Explore the full profile